Profile data is unavailable for this security.
About the company
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
- Revenue in USD (TTM)928.00k
- Net income in USD-11.11m
- Incorporated2012
- Employees10.00
- LocationRenovoRx Inc2570 W. EL CAMINO REAL, STE. 320,MOUNTAIN VIEW 94040United StatesUSA
- Phone+1 (408) 800-2649
- Fax+1 (302) 636-5454
- Websitehttps://renovorx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IRIDEX Corp | 50.65m | -5.09m | 24.24m | 93.00 | -- | -- | -- | 0.4786 | -0.3026 | -0.3026 | 3.02 | 0.2746 | 1.73 | 3.43 | 7.74 | 544,591.40 | -17.39 | -20.28 | -33.62 | -29.96 | 38.18 | 42.41 | -10.04 | -15.17 | 1.35 | -- | 0.4418 | -- | -6.17 | 2.30 | 6.90 | -- | -36.71 | -- |
| Global Innovative Platforms Inc | 30.00k | -647.22k | 24.24m | 52.00 | -- | 147.33 | -- | 808.04 | -0.0156 | -0.0156 | 0.0007 | 0.0035 | 0.1607 | -- | -- | -- | -346.65 | -- | -441.46 | -- | -- | -- | -2,157.40 | -- | -- | -- | 0.0185 | -- | -- | -- | -427.35 | -- | -- | -- |
| Inspira Technologies Oxy BHN Ltd | 289.00k | -11.21m | 25.96m | 38.00 | -- | 13.45 | -- | 89.84 | -0.4606 | -0.4606 | 0.0128 | 0.0446 | 0.0417 | 0.5281 | 0.6659 | 7,605.26 | -161.61 | -109.16 | -302.02 | -145.38 | 0.692 | -- | -3,879.24 | -- | 0.9002 | -- | 0.00 | -- | -- | -- | 2.06 | -- | 39.54 | -- |
| Harvard Bioscience Inc | 87.37m | -53.84m | 26.43m | 330.00 | -- | 1.87 | -- | 0.3025 | -1.22 | -1.22 | 1.98 | 0.3156 | 0.8352 | 1.58 | 7.01 | 264,760.60 | -51.46 | -4.48 | -81.52 | -5.47 | 56.94 | 57.18 | -61.62 | -6.18 | 0.4081 | -0.5686 | 0.7071 | -- | -16.14 | -4.12 | -263.25 | -- | 21.83 | -- |
| PetVivo Holdings Inc | 1.11m | -10.21m | 27.31m | 24.00 | -- | 7.96 | -- | 24.57 | -0.3857 | -0.3857 | 0.0411 | 0.0981 | 0.2969 | 0.7874 | 4.25 | 46,318.33 | -265.20 | -195.28 | -557.27 | -346.33 | 66.05 | 74.58 | -893.26 | -1,163.49 | 0.787 | -4.52 | 0.00 | -- | 16.91 | 216.08 | 23.33 | -- | 49.21 | -- |
| Myomo Inc | 41.64m | -12.02m | 28.85m | 184.00 | -- | 1.97 | -- | 0.6927 | -0.2885 | -0.2885 | 1.01 | 0.3805 | 1.65 | 3.96 | 9.23 | 226,321.70 | -47.71 | -55.96 | -70.30 | -77.40 | 66.56 | 69.74 | -28.86 | -52.92 | 2.10 | -- | 0.2148 | -- | 69.17 | 53.36 | 24.10 | -- | 92.10 | -- |
| Guided Therapeutics Inc | 178.00k | -2.80m | 29.26m | 4.00 | -- | -- | -- | 164.38 | -0.0386 | -0.0386 | 0.0025 | -0.0675 | 0.1654 | 0.1083 | 44.50 | 44,500.00 | -244.61 | -129.80 | -- | -- | 62.92 | 44.19 | -1,478.65 | -4,184.72 | 0.0334 | -4.13 | -- | -- | -92.86 | -27.93 | 31.07 | -- | -- | -- |
| Femasys Inc | 2.06m | -19.80m | 31.46m | 69.00 | -- | 5.59 | -- | 15.26 | -0.7198 | -0.7198 | 0.07 | 0.0963 | 0.1294 | 0.1973 | 4.34 | 29,876.81 | -124.24 | -63.09 | -214.46 | -74.30 | 63.05 | 66.63 | -960.53 | -961.82 | 0.6131 | -9.72 | 0.5982 | -- | 51.97 | 11.89 | -32.07 | -- | 4.01 | -- |
| Vaso Corp | 89.11m | 2.59m | 31.60m | 298.00 | 12.23 | 1.12 | 9.54 | 0.3546 | 0.0147 | 0.0147 | 0.5065 | 0.1605 | 1.13 | 34.02 | 10.28 | 299,030.20 | 3.27 | 7.37 | 5.36 | 14.56 | 60.91 | 59.17 | 2.91 | 5.99 | 1.61 | -- | 0.01 | -- | 7.09 | 2.82 | -80.21 | -- | 3.81 | -- |
| RenovoRx Inc | 928.00k | -11.11m | 32.32m | 10.00 | -- | 4.00 | -- | 34.83 | -0.4375 | -0.4375 | 0.0312 | 0.2204 | 0.0874 | -- | -- | 92,800.00 | -104.58 | -121.57 | -126.33 | -166.50 | 67.78 | -- | -1,196.66 | -90,830.23 | 5.68 | -- | 0.00 | -- | -- | -- | 13.86 | -- | -- | -- |
| EUDA Health Holdings Ltd | 5.16m | -2.06m | 32.98m | 117.00 | 56.47 | -- | -- | 6.39 | 0.0155 | 0.0876 | 0.1483 | -0.0998 | 2.49 | -- | 17.10 | 44,104.96 | -100.77 | -- | -- | -- | 22.39 | -- | -40.53 | -- | 0.2084 | -46.54 | -- | -- | 8.22 | -- | -108.62 | -- | -- | -- |
| Precision Optics Corporation Inc | 24.42m | -6.92m | 33.66m | 90.00 | -- | 3.61 | -- | 1.38 | -0.9286 | -0.9286 | 3.25 | 1.21 | 1.21 | 5.44 | 5.83 | 271,288.60 | -34.24 | -13.63 | -57.54 | -19.51 | 9.70 | 29.56 | -28.33 | -11.58 | 0.6188 | -36.73 | 0.1454 | -- | -0.0685 | 13.98 | -95.85 | -- | 7.81 | -- |
| Neuroone Medical Technologies Corp | 8.72m | -6.83m | 33.70m | 18.00 | -- | 5.25 | -- | 3.87 | -0.1648 | -0.1648 | 0.1936 | 0.1270 | 1.16 | 2.19 | 3.47 | 484,231.70 | -90.61 | -113.64 | -111.55 | -152.08 | 54.87 | 60.94 | -78.34 | -223.44 | 5.09 | -- | 0.1119 | -- | 250.35 | 44.41 | 70.73 | -- | -7.76 | -- |
| Ekso Bionics Holdings Inc | 12.80m | -11.92m | 36.45m | 50.00 | -- | 4.03 | -- | 2.85 | -5.09 | -5.09 | 5.28 | 2.54 | 0.5474 | 1.27 | 1.76 | 255,980.00 | -50.02 | -37.99 | -76.46 | -49.47 | 53.48 | 52.48 | -91.37 | -86.20 | 1.07 | -- | 0.31 | -- | -28.60 | 7.58 | -5.22 | -- | -- | -- |
| TELA Bio Inc | 77.06m | -39.00m | 37.68m | 209.00 | -- | 22.30 | -- | 0.4889 | -0.8863 | -0.8863 | 1.75 | 0.0386 | 1.34 | 2.01 | 6.85 | 368,684.20 | -68.06 | -51.29 | -96.57 | -60.70 | 67.23 | 66.26 | -50.61 | -88.02 | 2.62 | -7.25 | 0.9638 | -- | 18.56 | 35.02 | 18.91 | -- | -18.18 | -- |
| Vivos Inc | 48.63k | -3.01m | 38.36m | 10.00 | -- | 17.60 | -- | 788.91 | -0.0068 | -0.0068 | 0.0001 | 0.0048 | 0.0275 | -- | 10.03 | -- | -170.12 | -166.49 | -178.25 | -242.01 | -127.33 | 2.81 | -6,191.01 | -11,105.98 | 19.81 | -- | 0.00 | -- | 43.59 | 24.13 | -0.5424 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to RenovoRx Inc's reporting currency: US Dollar USD
16.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| AIGH Capital Management LLCas of 31 Dec 2025 | 2.83m | 7.73% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.45m | 3.95% |
| Bleichroeder LPas of 31 Dec 2025 | 600.00k | 1.64% |
| Geode Capital Management LLCas of 31 Dec 2025 | 371.39k | 1.01% |
| Wealthspire Advisors LLCas of 31 Dec 2025 | 252.53k | 0.69% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 157.90k | 0.43% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 117.46k | 0.32% |
| Nixon Peabody Trust Co. LLCas of 31 Dec 2025 | 97.17k | 0.27% |
| Chicago Partners Investment Group LLCas of 31 Dec 2025 | 92.36k | 0.25% |
| G1 Execution Services LLCas of 31 Dec 2025 | 90.01k | 0.25% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
